Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis.

British Journal of Clinical Pharmacology
Daniel R MoralesRobert W F Flynn

Abstract

Due to cardiovascular safety concerns, the European Medicines Agency (EMA) recommended new contraindications and changes to product information for diclofenac across Europe in 2013. This study aims to measure their impact among targeted populations. Quarterly interrupted time series regression (ITS) analyses of diclofenac initiation among cohorts with contraindications (congestive cardiac failure [CHF], ischaemic heart disease [IHD], peripheral arterial disease [PAD], cerebrovascular disease [CVD]) and cautions (hypertension, hyperlipidaemia, diabetes) from Denmark, the Netherlands, England and Scotland. The regulatory action was associated with significant immediate absolute reductions in diclofenac initiation in all countries for IHD (Denmark -0.08%, 95%CI -0.13, -0.03; England -0.09%, 95%CI -0.13 to -0.06%; the Netherlands -1.84%, 95%CI -2.51 to -1.17%; Scotland -0.34%, 95%CI -0.38 to -0.30%), PAD and hyperlipidaemia, the Netherlands, England and Scotland for hypertension and diabetes, and England and Scotland for CHF and CVD. Post-intervention there was a significant negative trend in diclofenac initiation in the Netherlands for IHD (-0.12%, 95%CI -0.19 to -0.04), PAD (-0.13%, 95%CI -0.22 to -0.05), hypertension, hyperlipid...Continue Reading

References

Aug 14, 2002·Journal of Clinical Pharmacy and Therapeutics·A K WagnerD Ross-Degnan
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Jun 7, 2011·Journal of Clinical Epidemiology·Fang ZhangDennis Ross-Degnan
Sep 3, 2011·Cardiovascular Therapeutics·Henry KrumChristopher P Cannon
Jun 1, 2013·Pharmacoepidemiology and Drug Safety·Yingjun ZhouAndrew N Freedman
Jun 27, 2014·European Journal of Epidemiology·Morten SchmidtHenrik Toft Sørensen
Jun 8, 2015·International Journal of Epidemiology·Emily HerrettLiam Smeeth
Nov 26, 2015·Clinical Epidemiology·Morten SchmidtHenrik Toft Sørensen
May 12, 2016·International Journal of Epidemiology·Samantha Alvarez-MadrazoMarion Bennie
Nov 7, 2017·British Journal of Clinical Pharmacology·Thomas GoedeckeXavier Kurz
Mar 4, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sieta T de VriesUNKNOWN SCOPE work package 6
Aug 2, 2019·British Journal of Clinical Pharmacology·Florence van HunselAgnes Kant
Feb 18, 2020·British Journal of Clinical Pharmacology·Peter Arlett

❮ Previous
Next ❯

Citations

Nov 14, 2020·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Aleksandra OpalskaHelga Gardarsdottir

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.